Company Overview

Update
Founded:
2007
Headquarters:
Baltimore, MD
Funding:
$48.4M
Categories:
Biotechnology
Description:
Gliknik develops therapies for patients with cancer and immune disorders.

Detailed Description

Update

Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves in off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the eficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to moncolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.

Current Team (3)

Update

Funding Rounds (8) - $48.4M

Update

Board Members and Advisors (4)

Update

Investors (2)

Update

Offices/Locations (1)

Update
  • Office

    801 W. Baltimore Street

    Suite 501A

    Baltimore, MD 21201

    USA

Images (1)

Update
  • A18bbe187cb85ec4fb87b0373ce4e972